HIV-IT gene therapy consisting of direct intramuscular injection of a mouse retrovector that delivers env and rev genes of HIV-1 to healthy cells data

VIGN (San Diego) reported interim analysis of Phase I safety and immunogenicity data on 21 patients. Testing of two dose levels versus placebo in these asymptomatic patients, who had CD4 counts above 400, showed enhanced activity of cytotoxic T lymphocytes that appears to be dose-dependent, the company announced at the meeting of the National Cooperative Vaccine Discovery Group for AIDS in Reston, Va. ...